Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Development programme

SUMMIT — tirzepatide in heart failure with preserved ejection fraction

A trial of tirzepatide in heart failure with preserved ejection fraction and obesity, with a composite of cardiovascular death and worsening heart failure among its primary endpoints.

A trial of tirzepatide in heart failure with preserved ejection fraction and obesity, with a composite of cardiovascular death and worsening heart failure among its primary endpoints.

Sponsor class: Manufacturer-sponsored. First record: 2021.

Showing 0 records on this page

Records in this programme

6 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
SUMMITTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled7312024Moderate
SUMMIT-ADHERENCEprogramme recordTirzepatidePhase 3ReportedObservational—2024Very low
SUMMIT-BIOMARKERprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
SUMMIT-ELDERLYprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
SUMMIT-OLEprogramme recordTirzepatidePhase 3ReportedSingle-arm open-label—2024Very low
SUMMIT-REGIONAL-JPprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.